Clinical Features of Chronic Obstructive Pulmonary Disease with High Fractional Exhaled Nitric Oxide
Background The fractional exhaled nitric oxide (FENO) test is useful in asthma patients. However, a few studies on its usefulness in chronic obstructive pulmonary disease (COPD) patients have been reported. We analyzed the FENO level distribution and clinical characteristics according to the FENO le...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Seong Ahn [verfasserIn] Tae-Ok Kim [verfasserIn] Jinsun Chang [verfasserIn] Hong-Joon Shin [verfasserIn] Yong-Soo Kwon [verfasserIn] Sung-Chul Lim [verfasserIn] Yu-Il Kim [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020 |
|---|
| Schlagwörter: |
pulmonary disease, chronic obstructive asthma-chronic obstructive pulmonary disease overlap syndrome |
|---|
| Übergeordnetes Werk: |
In: Tuberculosis and Respiratory Diseases - The Korean Academy of Tuberculosis and Respiratory Diseases, 2018, 83(2020), 3, Seite 234-241 |
|---|---|
| Übergeordnetes Werk: |
volume:83 ; year:2020 ; number:3 ; pages:234-241 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.4046/trd.2019.0086 |
|---|
| Katalog-ID: |
DOAJ043708404 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ043708404 | ||
| 003 | DE-627 | ||
| 005 | 20230502210908.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4046/trd.2019.0086 |2 doi | |
| 035 | |a (DE-627)DOAJ043708404 | ||
| 035 | |a (DE-599)DOAJ21bda3c2c4ce49688611ecb7701f9ba1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC705-779 | |
| 100 | 0 | |a Seong Ahn |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Features of Chronic Obstructive Pulmonary Disease with High Fractional Exhaled Nitric Oxide |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background The fractional exhaled nitric oxide (FENO) test is useful in asthma patients. However, a few studies on its usefulness in chronic obstructive pulmonary disease (COPD) patients have been reported. We analyzed the FENO level distribution and clinical characteristics according to the FENO level in COPD patients. Methods From December 2014 to June 2019, COPD patients who underwent pulmonary function and FENO tests at Chonnam National University Hospital were retrospectively evaluated for FENO, comorbidities, asthma history, blood eosinophil, and pulmonary function test. The high FENO group was defined as those with FENO level<25 parts per billion (ppb). Results A total of 849 COPD patients (mean age, 70.3±9.4 years) were included. The mean forced expiratory volume at 1 second was 66.5±21.7% and the mean FENO level was 24.3±20.5 ppb. Patients with FENO ≤25 ppb were 572 (67.4%) and those with FENO <25 ppb were 277 (32.6%). Blood eosinophil percentage was significantly higher (4.2±4.8 vs. 2.7±2.5, p<0.001) in patients with the high FENO group than the low FENO group. The high FENO group revealed a significantly higher frequency of patients with blood eosinophil percentage <3% (46.9% vs. 34.8%, p=0.001) and asthma history (25.6% vs. 8.6%, p<0.001) than the lower FENO group. Asthma history, blood eosinophil percentage <3%, and positive bronchodilator response (BDR) were independent risk factors for the high FENO level (adjusted odds ratio [aOR], 3.85; p<0.001; aOR, 1.46; p=0.017; and aOR, 1.57, p=0.034, respectively) in the multivariable analysis. Conclusion The FENO level distribution varied in COPD patients and the mean FENO value was slightly elevated. Asthma history, eosinophil percent, and positive BDR were independent risk factors for the high FENO level. | ||
| 650 | 4 | |a nitric oxide | |
| 650 | 4 | |a pulmonary disease, chronic obstructive | |
| 650 | 4 | |a asthma-chronic obstructive pulmonary disease overlap syndrome | |
| 653 | 0 | |a Diseases of the respiratory system | |
| 700 | 0 | |a Tae-Ok Kim |e verfasserin |4 aut | |
| 700 | 0 | |a Jinsun Chang |e verfasserin |4 aut | |
| 700 | 0 | |a Hong-Joon Shin |e verfasserin |4 aut | |
| 700 | 0 | |a Yong-Soo Kwon |e verfasserin |4 aut | |
| 700 | 0 | |a Sung-Chul Lim |e verfasserin |4 aut | |
| 700 | 0 | |a Yu-Il Kim |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Tuberculosis and Respiratory Diseases |d The Korean Academy of Tuberculosis and Respiratory Diseases, 2018 |g 83(2020), 3, Seite 234-241 |w (DE-627)1760599808 |x 20056184 |7 nnns |
| 773 | 1 | 8 | |g volume:83 |g year:2020 |g number:3 |g pages:234-241 |
| 856 | 4 | 0 | |u https://doi.org/10.4046/trd.2019.0086 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/21bda3c2c4ce49688611ecb7701f9ba1 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.e-trd.org/upload/pdf/trd-2019-0086.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1738-3536 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2005-6184 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 83 |j 2020 |e 3 |h 234-241 | ||
| author_variant |
s a sa t o k tok j c jc h j s hjs y s k ysk s c l scl y i k yik |
|---|---|
| matchkey_str |
article:20056184:2020----::lncletrsfhoiosrcieumnrdsaeihihrci |
| hierarchy_sort_str |
2020 |
| callnumber-subject-code |
RC |
| publishDate |
2020 |
| allfields |
10.4046/trd.2019.0086 doi (DE-627)DOAJ043708404 (DE-599)DOAJ21bda3c2c4ce49688611ecb7701f9ba1 DE-627 ger DE-627 rakwb eng RC705-779 Seong Ahn verfasserin aut Clinical Features of Chronic Obstructive Pulmonary Disease with High Fractional Exhaled Nitric Oxide 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background The fractional exhaled nitric oxide (FENO) test is useful in asthma patients. However, a few studies on its usefulness in chronic obstructive pulmonary disease (COPD) patients have been reported. We analyzed the FENO level distribution and clinical characteristics according to the FENO level in COPD patients. Methods From December 2014 to June 2019, COPD patients who underwent pulmonary function and FENO tests at Chonnam National University Hospital were retrospectively evaluated for FENO, comorbidities, asthma history, blood eosinophil, and pulmonary function test. The high FENO group was defined as those with FENO level<25 parts per billion (ppb). Results A total of 849 COPD patients (mean age, 70.3±9.4 years) were included. The mean forced expiratory volume at 1 second was 66.5±21.7% and the mean FENO level was 24.3±20.5 ppb. Patients with FENO ≤25 ppb were 572 (67.4%) and those with FENO <25 ppb were 277 (32.6%). Blood eosinophil percentage was significantly higher (4.2±4.8 vs. 2.7±2.5, p<0.001) in patients with the high FENO group than the low FENO group. The high FENO group revealed a significantly higher frequency of patients with blood eosinophil percentage <3% (46.9% vs. 34.8%, p=0.001) and asthma history (25.6% vs. 8.6%, p<0.001) than the lower FENO group. Asthma history, blood eosinophil percentage <3%, and positive bronchodilator response (BDR) were independent risk factors for the high FENO level (adjusted odds ratio [aOR], 3.85; p<0.001; aOR, 1.46; p=0.017; and aOR, 1.57, p=0.034, respectively) in the multivariable analysis. Conclusion The FENO level distribution varied in COPD patients and the mean FENO value was slightly elevated. Asthma history, eosinophil percent, and positive BDR were independent risk factors for the high FENO level. nitric oxide pulmonary disease, chronic obstructive asthma-chronic obstructive pulmonary disease overlap syndrome Diseases of the respiratory system Tae-Ok Kim verfasserin aut Jinsun Chang verfasserin aut Hong-Joon Shin verfasserin aut Yong-Soo Kwon verfasserin aut Sung-Chul Lim verfasserin aut Yu-Il Kim verfasserin aut In Tuberculosis and Respiratory Diseases The Korean Academy of Tuberculosis and Respiratory Diseases, 2018 83(2020), 3, Seite 234-241 (DE-627)1760599808 20056184 nnns volume:83 year:2020 number:3 pages:234-241 https://doi.org/10.4046/trd.2019.0086 kostenfrei https://doaj.org/article/21bda3c2c4ce49688611ecb7701f9ba1 kostenfrei http://www.e-trd.org/upload/pdf/trd-2019-0086.pdf kostenfrei https://doaj.org/toc/1738-3536 Journal toc kostenfrei https://doaj.org/toc/2005-6184 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 83 2020 3 234-241 |
| spelling |
10.4046/trd.2019.0086 doi (DE-627)DOAJ043708404 (DE-599)DOAJ21bda3c2c4ce49688611ecb7701f9ba1 DE-627 ger DE-627 rakwb eng RC705-779 Seong Ahn verfasserin aut Clinical Features of Chronic Obstructive Pulmonary Disease with High Fractional Exhaled Nitric Oxide 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background The fractional exhaled nitric oxide (FENO) test is useful in asthma patients. However, a few studies on its usefulness in chronic obstructive pulmonary disease (COPD) patients have been reported. We analyzed the FENO level distribution and clinical characteristics according to the FENO level in COPD patients. Methods From December 2014 to June 2019, COPD patients who underwent pulmonary function and FENO tests at Chonnam National University Hospital were retrospectively evaluated for FENO, comorbidities, asthma history, blood eosinophil, and pulmonary function test. The high FENO group was defined as those with FENO level<25 parts per billion (ppb). Results A total of 849 COPD patients (mean age, 70.3±9.4 years) were included. The mean forced expiratory volume at 1 second was 66.5±21.7% and the mean FENO level was 24.3±20.5 ppb. Patients with FENO ≤25 ppb were 572 (67.4%) and those with FENO <25 ppb were 277 (32.6%). Blood eosinophil percentage was significantly higher (4.2±4.8 vs. 2.7±2.5, p<0.001) in patients with the high FENO group than the low FENO group. The high FENO group revealed a significantly higher frequency of patients with blood eosinophil percentage <3% (46.9% vs. 34.8%, p=0.001) and asthma history (25.6% vs. 8.6%, p<0.001) than the lower FENO group. Asthma history, blood eosinophil percentage <3%, and positive bronchodilator response (BDR) were independent risk factors for the high FENO level (adjusted odds ratio [aOR], 3.85; p<0.001; aOR, 1.46; p=0.017; and aOR, 1.57, p=0.034, respectively) in the multivariable analysis. Conclusion The FENO level distribution varied in COPD patients and the mean FENO value was slightly elevated. Asthma history, eosinophil percent, and positive BDR were independent risk factors for the high FENO level. nitric oxide pulmonary disease, chronic obstructive asthma-chronic obstructive pulmonary disease overlap syndrome Diseases of the respiratory system Tae-Ok Kim verfasserin aut Jinsun Chang verfasserin aut Hong-Joon Shin verfasserin aut Yong-Soo Kwon verfasserin aut Sung-Chul Lim verfasserin aut Yu-Il Kim verfasserin aut In Tuberculosis and Respiratory Diseases The Korean Academy of Tuberculosis and Respiratory Diseases, 2018 83(2020), 3, Seite 234-241 (DE-627)1760599808 20056184 nnns volume:83 year:2020 number:3 pages:234-241 https://doi.org/10.4046/trd.2019.0086 kostenfrei https://doaj.org/article/21bda3c2c4ce49688611ecb7701f9ba1 kostenfrei http://www.e-trd.org/upload/pdf/trd-2019-0086.pdf kostenfrei https://doaj.org/toc/1738-3536 Journal toc kostenfrei https://doaj.org/toc/2005-6184 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 83 2020 3 234-241 |
| allfields_unstemmed |
10.4046/trd.2019.0086 doi (DE-627)DOAJ043708404 (DE-599)DOAJ21bda3c2c4ce49688611ecb7701f9ba1 DE-627 ger DE-627 rakwb eng RC705-779 Seong Ahn verfasserin aut Clinical Features of Chronic Obstructive Pulmonary Disease with High Fractional Exhaled Nitric Oxide 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background The fractional exhaled nitric oxide (FENO) test is useful in asthma patients. However, a few studies on its usefulness in chronic obstructive pulmonary disease (COPD) patients have been reported. We analyzed the FENO level distribution and clinical characteristics according to the FENO level in COPD patients. Methods From December 2014 to June 2019, COPD patients who underwent pulmonary function and FENO tests at Chonnam National University Hospital were retrospectively evaluated for FENO, comorbidities, asthma history, blood eosinophil, and pulmonary function test. The high FENO group was defined as those with FENO level<25 parts per billion (ppb). Results A total of 849 COPD patients (mean age, 70.3±9.4 years) were included. The mean forced expiratory volume at 1 second was 66.5±21.7% and the mean FENO level was 24.3±20.5 ppb. Patients with FENO ≤25 ppb were 572 (67.4%) and those with FENO <25 ppb were 277 (32.6%). Blood eosinophil percentage was significantly higher (4.2±4.8 vs. 2.7±2.5, p<0.001) in patients with the high FENO group than the low FENO group. The high FENO group revealed a significantly higher frequency of patients with blood eosinophil percentage <3% (46.9% vs. 34.8%, p=0.001) and asthma history (25.6% vs. 8.6%, p<0.001) than the lower FENO group. Asthma history, blood eosinophil percentage <3%, and positive bronchodilator response (BDR) were independent risk factors for the high FENO level (adjusted odds ratio [aOR], 3.85; p<0.001; aOR, 1.46; p=0.017; and aOR, 1.57, p=0.034, respectively) in the multivariable analysis. Conclusion The FENO level distribution varied in COPD patients and the mean FENO value was slightly elevated. Asthma history, eosinophil percent, and positive BDR were independent risk factors for the high FENO level. nitric oxide pulmonary disease, chronic obstructive asthma-chronic obstructive pulmonary disease overlap syndrome Diseases of the respiratory system Tae-Ok Kim verfasserin aut Jinsun Chang verfasserin aut Hong-Joon Shin verfasserin aut Yong-Soo Kwon verfasserin aut Sung-Chul Lim verfasserin aut Yu-Il Kim verfasserin aut In Tuberculosis and Respiratory Diseases The Korean Academy of Tuberculosis and Respiratory Diseases, 2018 83(2020), 3, Seite 234-241 (DE-627)1760599808 20056184 nnns volume:83 year:2020 number:3 pages:234-241 https://doi.org/10.4046/trd.2019.0086 kostenfrei https://doaj.org/article/21bda3c2c4ce49688611ecb7701f9ba1 kostenfrei http://www.e-trd.org/upload/pdf/trd-2019-0086.pdf kostenfrei https://doaj.org/toc/1738-3536 Journal toc kostenfrei https://doaj.org/toc/2005-6184 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 83 2020 3 234-241 |
| allfieldsGer |
10.4046/trd.2019.0086 doi (DE-627)DOAJ043708404 (DE-599)DOAJ21bda3c2c4ce49688611ecb7701f9ba1 DE-627 ger DE-627 rakwb eng RC705-779 Seong Ahn verfasserin aut Clinical Features of Chronic Obstructive Pulmonary Disease with High Fractional Exhaled Nitric Oxide 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background The fractional exhaled nitric oxide (FENO) test is useful in asthma patients. However, a few studies on its usefulness in chronic obstructive pulmonary disease (COPD) patients have been reported. We analyzed the FENO level distribution and clinical characteristics according to the FENO level in COPD patients. Methods From December 2014 to June 2019, COPD patients who underwent pulmonary function and FENO tests at Chonnam National University Hospital were retrospectively evaluated for FENO, comorbidities, asthma history, blood eosinophil, and pulmonary function test. The high FENO group was defined as those with FENO level<25 parts per billion (ppb). Results A total of 849 COPD patients (mean age, 70.3±9.4 years) were included. The mean forced expiratory volume at 1 second was 66.5±21.7% and the mean FENO level was 24.3±20.5 ppb. Patients with FENO ≤25 ppb were 572 (67.4%) and those with FENO <25 ppb were 277 (32.6%). Blood eosinophil percentage was significantly higher (4.2±4.8 vs. 2.7±2.5, p<0.001) in patients with the high FENO group than the low FENO group. The high FENO group revealed a significantly higher frequency of patients with blood eosinophil percentage <3% (46.9% vs. 34.8%, p=0.001) and asthma history (25.6% vs. 8.6%, p<0.001) than the lower FENO group. Asthma history, blood eosinophil percentage <3%, and positive bronchodilator response (BDR) were independent risk factors for the high FENO level (adjusted odds ratio [aOR], 3.85; p<0.001; aOR, 1.46; p=0.017; and aOR, 1.57, p=0.034, respectively) in the multivariable analysis. Conclusion The FENO level distribution varied in COPD patients and the mean FENO value was slightly elevated. Asthma history, eosinophil percent, and positive BDR were independent risk factors for the high FENO level. nitric oxide pulmonary disease, chronic obstructive asthma-chronic obstructive pulmonary disease overlap syndrome Diseases of the respiratory system Tae-Ok Kim verfasserin aut Jinsun Chang verfasserin aut Hong-Joon Shin verfasserin aut Yong-Soo Kwon verfasserin aut Sung-Chul Lim verfasserin aut Yu-Il Kim verfasserin aut In Tuberculosis and Respiratory Diseases The Korean Academy of Tuberculosis and Respiratory Diseases, 2018 83(2020), 3, Seite 234-241 (DE-627)1760599808 20056184 nnns volume:83 year:2020 number:3 pages:234-241 https://doi.org/10.4046/trd.2019.0086 kostenfrei https://doaj.org/article/21bda3c2c4ce49688611ecb7701f9ba1 kostenfrei http://www.e-trd.org/upload/pdf/trd-2019-0086.pdf kostenfrei https://doaj.org/toc/1738-3536 Journal toc kostenfrei https://doaj.org/toc/2005-6184 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 83 2020 3 234-241 |
| allfieldsSound |
10.4046/trd.2019.0086 doi (DE-627)DOAJ043708404 (DE-599)DOAJ21bda3c2c4ce49688611ecb7701f9ba1 DE-627 ger DE-627 rakwb eng RC705-779 Seong Ahn verfasserin aut Clinical Features of Chronic Obstructive Pulmonary Disease with High Fractional Exhaled Nitric Oxide 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background The fractional exhaled nitric oxide (FENO) test is useful in asthma patients. However, a few studies on its usefulness in chronic obstructive pulmonary disease (COPD) patients have been reported. We analyzed the FENO level distribution and clinical characteristics according to the FENO level in COPD patients. Methods From December 2014 to June 2019, COPD patients who underwent pulmonary function and FENO tests at Chonnam National University Hospital were retrospectively evaluated for FENO, comorbidities, asthma history, blood eosinophil, and pulmonary function test. The high FENO group was defined as those with FENO level<25 parts per billion (ppb). Results A total of 849 COPD patients (mean age, 70.3±9.4 years) were included. The mean forced expiratory volume at 1 second was 66.5±21.7% and the mean FENO level was 24.3±20.5 ppb. Patients with FENO ≤25 ppb were 572 (67.4%) and those with FENO <25 ppb were 277 (32.6%). Blood eosinophil percentage was significantly higher (4.2±4.8 vs. 2.7±2.5, p<0.001) in patients with the high FENO group than the low FENO group. The high FENO group revealed a significantly higher frequency of patients with blood eosinophil percentage <3% (46.9% vs. 34.8%, p=0.001) and asthma history (25.6% vs. 8.6%, p<0.001) than the lower FENO group. Asthma history, blood eosinophil percentage <3%, and positive bronchodilator response (BDR) were independent risk factors for the high FENO level (adjusted odds ratio [aOR], 3.85; p<0.001; aOR, 1.46; p=0.017; and aOR, 1.57, p=0.034, respectively) in the multivariable analysis. Conclusion The FENO level distribution varied in COPD patients and the mean FENO value was slightly elevated. Asthma history, eosinophil percent, and positive BDR were independent risk factors for the high FENO level. nitric oxide pulmonary disease, chronic obstructive asthma-chronic obstructive pulmonary disease overlap syndrome Diseases of the respiratory system Tae-Ok Kim verfasserin aut Jinsun Chang verfasserin aut Hong-Joon Shin verfasserin aut Yong-Soo Kwon verfasserin aut Sung-Chul Lim verfasserin aut Yu-Il Kim verfasserin aut In Tuberculosis and Respiratory Diseases The Korean Academy of Tuberculosis and Respiratory Diseases, 2018 83(2020), 3, Seite 234-241 (DE-627)1760599808 20056184 nnns volume:83 year:2020 number:3 pages:234-241 https://doi.org/10.4046/trd.2019.0086 kostenfrei https://doaj.org/article/21bda3c2c4ce49688611ecb7701f9ba1 kostenfrei http://www.e-trd.org/upload/pdf/trd-2019-0086.pdf kostenfrei https://doaj.org/toc/1738-3536 Journal toc kostenfrei https://doaj.org/toc/2005-6184 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 83 2020 3 234-241 |
| language |
English |
| source |
In Tuberculosis and Respiratory Diseases 83(2020), 3, Seite 234-241 volume:83 year:2020 number:3 pages:234-241 |
| sourceStr |
In Tuberculosis and Respiratory Diseases 83(2020), 3, Seite 234-241 volume:83 year:2020 number:3 pages:234-241 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
nitric oxide pulmonary disease, chronic obstructive asthma-chronic obstructive pulmonary disease overlap syndrome Diseases of the respiratory system |
| isfreeaccess_bool |
true |
| container_title |
Tuberculosis and Respiratory Diseases |
| authorswithroles_txt_mv |
Seong Ahn @@aut@@ Tae-Ok Kim @@aut@@ Jinsun Chang @@aut@@ Hong-Joon Shin @@aut@@ Yong-Soo Kwon @@aut@@ Sung-Chul Lim @@aut@@ Yu-Il Kim @@aut@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
1760599808 |
| id |
DOAJ043708404 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ043708404</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502210908.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.4046/trd.2019.0086</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ043708404</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ21bda3c2c4ce49688611ecb7701f9ba1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC705-779</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Seong Ahn</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical Features of Chronic Obstructive Pulmonary Disease with High Fractional Exhaled Nitric Oxide</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background The fractional exhaled nitric oxide (FENO) test is useful in asthma patients. However, a few studies on its usefulness in chronic obstructive pulmonary disease (COPD) patients have been reported. We analyzed the FENO level distribution and clinical characteristics according to the FENO level in COPD patients. Methods From December 2014 to June 2019, COPD patients who underwent pulmonary function and FENO tests at Chonnam National University Hospital were retrospectively evaluated for FENO, comorbidities, asthma history, blood eosinophil, and pulmonary function test. The high FENO group was defined as those with FENO level<25 parts per billion (ppb). Results A total of 849 COPD patients (mean age, 70.3±9.4 years) were included. The mean forced expiratory volume at 1 second was 66.5±21.7% and the mean FENO level was 24.3±20.5 ppb. Patients with FENO ≤25 ppb were 572 (67.4%) and those with FENO <25 ppb were 277 (32.6%). Blood eosinophil percentage was significantly higher (4.2±4.8 vs. 2.7±2.5, p<0.001) in patients with the high FENO group than the low FENO group. The high FENO group revealed a significantly higher frequency of patients with blood eosinophil percentage <3% (46.9% vs. 34.8%, p=0.001) and asthma history (25.6% vs. 8.6%, p<0.001) than the lower FENO group. Asthma history, blood eosinophil percentage <3%, and positive bronchodilator response (BDR) were independent risk factors for the high FENO level (adjusted odds ratio [aOR], 3.85; p<0.001; aOR, 1.46; p=0.017; and aOR, 1.57, p=0.034, respectively) in the multivariable analysis. Conclusion The FENO level distribution varied in COPD patients and the mean FENO value was slightly elevated. Asthma history, eosinophil percent, and positive BDR were independent risk factors for the high FENO level.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nitric oxide</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pulmonary disease, chronic obstructive</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">asthma-chronic obstructive pulmonary disease overlap syndrome</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the respiratory system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tae-Ok Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jinsun Chang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hong-Joon Shin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yong-Soo Kwon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sung-Chul Lim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yu-Il Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Tuberculosis and Respiratory Diseases</subfield><subfield code="d">The Korean Academy of Tuberculosis and Respiratory Diseases, 2018</subfield><subfield code="g">83(2020), 3, Seite 234-241</subfield><subfield code="w">(DE-627)1760599808</subfield><subfield code="x">20056184</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:83</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:234-241</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.4046/trd.2019.0086</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/21bda3c2c4ce49688611ecb7701f9ba1</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.e-trd.org/upload/pdf/trd-2019-0086.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1738-3536</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2005-6184</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">83</subfield><subfield code="j">2020</subfield><subfield code="e">3</subfield><subfield code="h">234-241</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Seong Ahn |
| spellingShingle |
Seong Ahn misc RC705-779 misc nitric oxide misc pulmonary disease, chronic obstructive misc asthma-chronic obstructive pulmonary disease overlap syndrome misc Diseases of the respiratory system Clinical Features of Chronic Obstructive Pulmonary Disease with High Fractional Exhaled Nitric Oxide |
| authorStr |
Seong Ahn |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760599808 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RC705-779 |
| illustrated |
Not Illustrated |
| issn |
20056184 |
| topic_title |
RC705-779 Clinical Features of Chronic Obstructive Pulmonary Disease with High Fractional Exhaled Nitric Oxide nitric oxide pulmonary disease, chronic obstructive asthma-chronic obstructive pulmonary disease overlap syndrome |
| topic |
misc RC705-779 misc nitric oxide misc pulmonary disease, chronic obstructive misc asthma-chronic obstructive pulmonary disease overlap syndrome misc Diseases of the respiratory system |
| topic_unstemmed |
misc RC705-779 misc nitric oxide misc pulmonary disease, chronic obstructive misc asthma-chronic obstructive pulmonary disease overlap syndrome misc Diseases of the respiratory system |
| topic_browse |
misc RC705-779 misc nitric oxide misc pulmonary disease, chronic obstructive misc asthma-chronic obstructive pulmonary disease overlap syndrome misc Diseases of the respiratory system |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Tuberculosis and Respiratory Diseases |
| hierarchy_parent_id |
1760599808 |
| hierarchy_top_title |
Tuberculosis and Respiratory Diseases |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760599808 |
| title |
Clinical Features of Chronic Obstructive Pulmonary Disease with High Fractional Exhaled Nitric Oxide |
| ctrlnum |
(DE-627)DOAJ043708404 (DE-599)DOAJ21bda3c2c4ce49688611ecb7701f9ba1 |
| title_full |
Clinical Features of Chronic Obstructive Pulmonary Disease with High Fractional Exhaled Nitric Oxide |
| author_sort |
Seong Ahn |
| journal |
Tuberculosis and Respiratory Diseases |
| journalStr |
Tuberculosis and Respiratory Diseases |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
txt |
| container_start_page |
234 |
| author_browse |
Seong Ahn Tae-Ok Kim Jinsun Chang Hong-Joon Shin Yong-Soo Kwon Sung-Chul Lim Yu-Il Kim |
| container_volume |
83 |
| class |
RC705-779 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Seong Ahn |
| doi_str_mv |
10.4046/trd.2019.0086 |
| author2-role |
verfasserin |
| title_sort |
clinical features of chronic obstructive pulmonary disease with high fractional exhaled nitric oxide |
| callnumber |
RC705-779 |
| title_auth |
Clinical Features of Chronic Obstructive Pulmonary Disease with High Fractional Exhaled Nitric Oxide |
| abstract |
Background The fractional exhaled nitric oxide (FENO) test is useful in asthma patients. However, a few studies on its usefulness in chronic obstructive pulmonary disease (COPD) patients have been reported. We analyzed the FENO level distribution and clinical characteristics according to the FENO level in COPD patients. Methods From December 2014 to June 2019, COPD patients who underwent pulmonary function and FENO tests at Chonnam National University Hospital were retrospectively evaluated for FENO, comorbidities, asthma history, blood eosinophil, and pulmonary function test. The high FENO group was defined as those with FENO level<25 parts per billion (ppb). Results A total of 849 COPD patients (mean age, 70.3±9.4 years) were included. The mean forced expiratory volume at 1 second was 66.5±21.7% and the mean FENO level was 24.3±20.5 ppb. Patients with FENO ≤25 ppb were 572 (67.4%) and those with FENO <25 ppb were 277 (32.6%). Blood eosinophil percentage was significantly higher (4.2±4.8 vs. 2.7±2.5, p<0.001) in patients with the high FENO group than the low FENO group. The high FENO group revealed a significantly higher frequency of patients with blood eosinophil percentage <3% (46.9% vs. 34.8%, p=0.001) and asthma history (25.6% vs. 8.6%, p<0.001) than the lower FENO group. Asthma history, blood eosinophil percentage <3%, and positive bronchodilator response (BDR) were independent risk factors for the high FENO level (adjusted odds ratio [aOR], 3.85; p<0.001; aOR, 1.46; p=0.017; and aOR, 1.57, p=0.034, respectively) in the multivariable analysis. Conclusion The FENO level distribution varied in COPD patients and the mean FENO value was slightly elevated. Asthma history, eosinophil percent, and positive BDR were independent risk factors for the high FENO level. |
| abstractGer |
Background The fractional exhaled nitric oxide (FENO) test is useful in asthma patients. However, a few studies on its usefulness in chronic obstructive pulmonary disease (COPD) patients have been reported. We analyzed the FENO level distribution and clinical characteristics according to the FENO level in COPD patients. Methods From December 2014 to June 2019, COPD patients who underwent pulmonary function and FENO tests at Chonnam National University Hospital were retrospectively evaluated for FENO, comorbidities, asthma history, blood eosinophil, and pulmonary function test. The high FENO group was defined as those with FENO level<25 parts per billion (ppb). Results A total of 849 COPD patients (mean age, 70.3±9.4 years) were included. The mean forced expiratory volume at 1 second was 66.5±21.7% and the mean FENO level was 24.3±20.5 ppb. Patients with FENO ≤25 ppb were 572 (67.4%) and those with FENO <25 ppb were 277 (32.6%). Blood eosinophil percentage was significantly higher (4.2±4.8 vs. 2.7±2.5, p<0.001) in patients with the high FENO group than the low FENO group. The high FENO group revealed a significantly higher frequency of patients with blood eosinophil percentage <3% (46.9% vs. 34.8%, p=0.001) and asthma history (25.6% vs. 8.6%, p<0.001) than the lower FENO group. Asthma history, blood eosinophil percentage <3%, and positive bronchodilator response (BDR) were independent risk factors for the high FENO level (adjusted odds ratio [aOR], 3.85; p<0.001; aOR, 1.46; p=0.017; and aOR, 1.57, p=0.034, respectively) in the multivariable analysis. Conclusion The FENO level distribution varied in COPD patients and the mean FENO value was slightly elevated. Asthma history, eosinophil percent, and positive BDR were independent risk factors for the high FENO level. |
| abstract_unstemmed |
Background The fractional exhaled nitric oxide (FENO) test is useful in asthma patients. However, a few studies on its usefulness in chronic obstructive pulmonary disease (COPD) patients have been reported. We analyzed the FENO level distribution and clinical characteristics according to the FENO level in COPD patients. Methods From December 2014 to June 2019, COPD patients who underwent pulmonary function and FENO tests at Chonnam National University Hospital were retrospectively evaluated for FENO, comorbidities, asthma history, blood eosinophil, and pulmonary function test. The high FENO group was defined as those with FENO level<25 parts per billion (ppb). Results A total of 849 COPD patients (mean age, 70.3±9.4 years) were included. The mean forced expiratory volume at 1 second was 66.5±21.7% and the mean FENO level was 24.3±20.5 ppb. Patients with FENO ≤25 ppb were 572 (67.4%) and those with FENO <25 ppb were 277 (32.6%). Blood eosinophil percentage was significantly higher (4.2±4.8 vs. 2.7±2.5, p<0.001) in patients with the high FENO group than the low FENO group. The high FENO group revealed a significantly higher frequency of patients with blood eosinophil percentage <3% (46.9% vs. 34.8%, p=0.001) and asthma history (25.6% vs. 8.6%, p<0.001) than the lower FENO group. Asthma history, blood eosinophil percentage <3%, and positive bronchodilator response (BDR) were independent risk factors for the high FENO level (adjusted odds ratio [aOR], 3.85; p<0.001; aOR, 1.46; p=0.017; and aOR, 1.57, p=0.034, respectively) in the multivariable analysis. Conclusion The FENO level distribution varied in COPD patients and the mean FENO value was slightly elevated. Asthma history, eosinophil percent, and positive BDR were independent risk factors for the high FENO level. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA |
| container_issue |
3 |
| title_short |
Clinical Features of Chronic Obstructive Pulmonary Disease with High Fractional Exhaled Nitric Oxide |
| url |
https://doi.org/10.4046/trd.2019.0086 https://doaj.org/article/21bda3c2c4ce49688611ecb7701f9ba1 http://www.e-trd.org/upload/pdf/trd-2019-0086.pdf https://doaj.org/toc/1738-3536 https://doaj.org/toc/2005-6184 |
| remote_bool |
true |
| author2 |
Tae-Ok Kim Jinsun Chang Hong-Joon Shin Yong-Soo Kwon Sung-Chul Lim Yu-Il Kim |
| author2Str |
Tae-Ok Kim Jinsun Chang Hong-Joon Shin Yong-Soo Kwon Sung-Chul Lim Yu-Il Kim |
| ppnlink |
1760599808 |
| callnumber-subject |
RC - Internal Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.4046/trd.2019.0086 |
| callnumber-a |
RC705-779 |
| up_date |
2024-07-03T19:02:52.355Z |
| _version_ |
1803585713455759360 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ043708404</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502210908.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.4046/trd.2019.0086</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ043708404</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ21bda3c2c4ce49688611ecb7701f9ba1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC705-779</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Seong Ahn</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical Features of Chronic Obstructive Pulmonary Disease with High Fractional Exhaled Nitric Oxide</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background The fractional exhaled nitric oxide (FENO) test is useful in asthma patients. However, a few studies on its usefulness in chronic obstructive pulmonary disease (COPD) patients have been reported. We analyzed the FENO level distribution and clinical characteristics according to the FENO level in COPD patients. Methods From December 2014 to June 2019, COPD patients who underwent pulmonary function and FENO tests at Chonnam National University Hospital were retrospectively evaluated for FENO, comorbidities, asthma history, blood eosinophil, and pulmonary function test. The high FENO group was defined as those with FENO level<25 parts per billion (ppb). Results A total of 849 COPD patients (mean age, 70.3±9.4 years) were included. The mean forced expiratory volume at 1 second was 66.5±21.7% and the mean FENO level was 24.3±20.5 ppb. Patients with FENO ≤25 ppb were 572 (67.4%) and those with FENO <25 ppb were 277 (32.6%). Blood eosinophil percentage was significantly higher (4.2±4.8 vs. 2.7±2.5, p<0.001) in patients with the high FENO group than the low FENO group. The high FENO group revealed a significantly higher frequency of patients with blood eosinophil percentage <3% (46.9% vs. 34.8%, p=0.001) and asthma history (25.6% vs. 8.6%, p<0.001) than the lower FENO group. Asthma history, blood eosinophil percentage <3%, and positive bronchodilator response (BDR) were independent risk factors for the high FENO level (adjusted odds ratio [aOR], 3.85; p<0.001; aOR, 1.46; p=0.017; and aOR, 1.57, p=0.034, respectively) in the multivariable analysis. Conclusion The FENO level distribution varied in COPD patients and the mean FENO value was slightly elevated. Asthma history, eosinophil percent, and positive BDR were independent risk factors for the high FENO level.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nitric oxide</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pulmonary disease, chronic obstructive</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">asthma-chronic obstructive pulmonary disease overlap syndrome</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the respiratory system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tae-Ok Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jinsun Chang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hong-Joon Shin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yong-Soo Kwon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sung-Chul Lim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yu-Il Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Tuberculosis and Respiratory Diseases</subfield><subfield code="d">The Korean Academy of Tuberculosis and Respiratory Diseases, 2018</subfield><subfield code="g">83(2020), 3, Seite 234-241</subfield><subfield code="w">(DE-627)1760599808</subfield><subfield code="x">20056184</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:83</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:234-241</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.4046/trd.2019.0086</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/21bda3c2c4ce49688611ecb7701f9ba1</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.e-trd.org/upload/pdf/trd-2019-0086.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1738-3536</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2005-6184</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">83</subfield><subfield code="j">2020</subfield><subfield code="e">3</subfield><subfield code="h">234-241</subfield></datafield></record></collection>
|
| score |
7.400754 |